SAPRO CRO

For U.S., biotech and medical device startups, early clinical development is rarely linear. Scientific uncertainty, evolving regulatory expectations and investor-driven timelines frequently collide at the earliest stages of human research. Increasingly, early-phase clinical studies conducted in Australia and New Zealand are playing a strategic role in helping sponsors navigate this complexity as programs move from concept to clinic.

In this environment, early trials are not isolated activities, they are decision points along a broader development pathway.

As a result, startups are moving away from transactional outsourcing models toward long-term trial pathway partnerships that support programs end-to-end rather than study by study.

Drawing on experience across pioneering medical device clinical research and pharmaceutical development, Rhona Macdonald, Director of Clinical Innovation and Delivery at SAPRO, brings a senior leadership perspective to pathway-driven early clinical development across Australia and New Zealand.

Early Trials as Strategic Milestones

Small and early-phase trials carry disproportionate importance for startup sponsors. These studies must generate credible, decision-making data that supports multiple downstream objectives, from regulatory engagement and technical refinement to future fundraising.

For both biotech and device companies, success in early development depends on:

• Fit-for-purpose protocol design aligned to the next development decision

• Efficient execution without unnecessary operational complexity

• Data packages that remain relevant beyond the immediate study

This has driven a shift away from transactional, high-throughput outsourcing models typically designed for scale toward trial pathway partnerships built around long-term program understanding continuity and strategic foresight.

Australia and New Zealand as Connected Trial Regions

Australia and New Zealand are both recognized as strong environments for early clinical research. Both offer efficient regulatory and ethics pathways, experienced investigators and high-quality research infrastructure across pharmaceutical and medical device development, including first-in-human studies.

Beyond operational and regulatory strengths, government-supported R&D and clinical trial incentive frameworks in both countries further support early development programs, particularly for startup sponsors seeking to manage capital efficiently while generating robust clinical data.

“Rather than focusing solely on study delivery, trial pathway partnerships emphasize continuity, foresight and adaptability across the clinical lifecycle. This approach is particularly well suited to startup sponsors navigating their first clinical milestones.”

Together, Australia and New Zealand provide:

• Regionally aligned regulatory and ethics frameworks

• Access to specialist clinical sites and investigators experienced in early-phase and device studies

• Established R&D and clinical trial incentive environments

• A pragmatic setting for generating high-quality early human data efficiently

For US startups, the ability to run studies across both countries through a single, integrated partnership simplifies execution while preserving flexibility as programs evolve.

Experience That Shapes the Trial Pathway Approach

The shift toward pathway-driven partnerships is informed by experience across both medical device and pharmaceutical development.

Insights gained from early feasibility and first-inhuman device studies highlight how initial clinical decisions influence not only regulatory outcomes, but also design refinement, procedural workflows and long-term clinical adoption. Similarly, experience in pharmaceutical development reinforces the importance of aligning early trials with clearly defined regulatory and commercial endpoints.

Bringing these perspectives together at a senior leadership level enables a more integrated approach to early development and one that recognizes how decisions made in early-phase studies shape everything that follows. This collective experience underpins the trial pathway model, where each study is designed with a clear line of sight to the next milestone.

The Trial Pathway Partner Model

Rather than focusing solely on study delivery, trial pathway partnerships emphasize continuity, foresight and adaptability across the clinical lifecycle. This approach is particularly well suited to startup sponsors navigating their first clinical milestones.

Key elements of this model include:

• Early involvement in clinical strategy, feasibility and protocol design

• Senior-level oversight maintained throughout the program

• Proactive risk identification and mitigation

• Alignment of early trials with future regulatory and development pathways

By maintaining a clear line of sight from early feasibility through to defined next-stage decision points, this model helps ensure that each study meaningfully advances the overall program.

Supporting US Startups Beyond Operations

For lean US biotech and device companies, a trial pathway partner often functions as an extension of the internal team. Beyond operational execution, this support can include:

• Translating regional trial outputs into data suitable for FDA interactions

• Advising on the transition from early ANZ studies to subsequent development decision

• Supporting decision-making as scientific or funding conditions change

In medical device programs, this collaborative approach also allows early clinical insights to inform design refinement before larger or pivotal studies commence, reducing downstream risk.

A Model Aligned to the Future of Early Development

As innovation continues to shift toward smaller, highly specialized biotech and medical device companies, the clinical research ecosystem is evolving in response. Trial pathway partnerships, particularly those spanning Australia and New Zealand, offer US startups a collaborative, globally connected approach to early clinical development.

By treating each study as part of a broader pathway rather than a standalone event, this model supports smarter decision-making, protects early-stage value and helps emerging companies move forward with confidence.